The results indicated that the mRNA expressions of COL1A1, CTGF, fibronectin, and α-SMA were significantly raised with tunicamycin treatment, and the changes were lowered with BRI, LAT, or OMD cotreatment significantly compared to the tunicamycin-treated group. This evidence concerns the gene ITM2B and occult macular dystrophy.